Androgen receptor assay – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 05 Jun 2026 10:52:02 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Androgen receptor assay – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effects of Vosilasarm Alone and in Combination for Patients with Relapsed Advanced or Metastatic Breast Cancer https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-vosilasarm-alone-and-in-combination-for-patients-with-relapsed-advanced-or-metastatic-breast-cancer/ Wed, 29 Apr 2026 14:57:26 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-vosilasarm-alone-and-in-combination-for-patients-with-relapsed-advanced-or-metastatic-breast-cancer/ This clinical trial is focused on studying a type of cancer known as breast cancer, specifically in patients whose cancer has returned or spread to other parts of the body. The study is investigating a new treatment called EP0062, which is a tablet taken by mouth. EP0062 is also known by its chemical name, vosilasarm, and is a type of medication called an oral selective androgen receptor modulator. This trial aims to understand how safe and tolerable EP0062 is when used alone and in combination with other treatments.

The study is divided into two parts. In the first part, researchers will determine the best dose of EP0062 when used by itself. In the second part, they will explore how EP0062 works when combined with other standard treatments for breast cancer. The goal is to find the most effective and safe way to use EP0062 for patients with AR-positive, HER2-negative, and ER-positive breast cancer. These terms refer to specific characteristics of the cancer cells that can influence how the cancer behaves and responds to treatment.

Throughout the study, participants will be closely monitored for any side effects and how their cancer responds to the treatment. The trial will help determine the optimal dose of EP0062 and assess its potential benefits for patients with advanced breast cancer. This research is important for developing new treatment options for individuals with this type of cancer.

]]>